Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
2 FDA citations trouble Hengrui, Elevar's liver cancer combo
Following resolution of the problem cited in the CRL, investors questioned why the FDA issued a swift rejection instead of waiting for the PDUFA date.
Angus Liu
Jul 28, 2026 3:02pm
J&J proposes $5.5B deal to resolve 76,000 ovarian cancer claims
Jul 28, 2026 11:26am
The CSO Model Is Endangered. Here’s How to Evolve.
Brought to you by
Mix Talent
Regulatory tracker: MannKind's edema autoinjector nets FDA nod
Jul 28, 2026 10:20am
Designing an agentic, future‑ready tech roadmap for emerging pharma
Brought to you by
ZS
GSK CEO targets mature products, procurement for cost savings
Jul 28, 2026 9:45am
